After Reaching Milestone, Is Zai Lab Limited – American Depositary Shares (NASDAQ:ZLAB)’s Short Interest Revealing Something?

June 16, 2018 - By Migdalia James

The stock of Zai Lab Limited – American Depositary Shares (NASDAQ:ZLAB) registered a decrease of 0.01% in short interest. ZLAB’s total short interest was 1.85 million shares in June as published by FINRA. Its down 0.01% from 1.86M shares, reported previously. With 60,300 shares average volume, it will take short sellers 31 days to cover their ZLAB’s short positions. The short interest to Zai Lab Limited – American Depositary Shares’s float is 65.15%.

The stock increased 0.50% or $0.12 during the last trading session, reaching $23.95. About 90,526 shares traded or 1.28% up from the average. Zai Lab Limited (NASDAQ:ZLAB) has 0.00% since June 16, 2017 and is . It has underperformed by 12.57% the S&P500.

Zai Lab Limited, a biopharmaceutical company, engages in discovering or licensing, developing, and commercializing proprietary therapeutics for oncology, and autoimmune and infectious disease therapies in China. The company has market cap of $1.21 billion. The Company’s drug candidates include ZL-2306, a poly ADP ribose polymerase 1/2 inhibitor for the treatment of ovarian, breast, and lung cancers; ZL-2401, an antibiotic for the treatment of acute bacterial skin/skin structure infections, community-acquired bacterial pneumonias, and urinary tract infections; ZL-2301 that is Phase II clinical trial for the treatment of hepatocellular carcinoma; ZL-3101, a novel steroid-sparing topical product that is in Phase II clinical trial for the treatment of eczema and psoriasis; ZL-2302 for the treatment of non-small cell lung cancer; and ZL-1101, an anti-OX40 antagonistic antibody for the treatment of graft-versus-host disease or systemic lupus erythematosus. It currently has negative earnings.

More notable recent Zai Lab Limited (NASDAQ:ZLAB) news were published by: Nasdaq.com which released: “Zai Lab and Crescendo Biologics Enter Exclusive Worldwide License Agreement for Innovative Protein Therapeutics …” on May 30, 2018, also Benzinga.com with their article: “42 Biggest Movers From Friday” published on May 29, 2018, Nasdaq.com published: “Zai Lab Expands Commercial Leadership Team, Appoints William Liang as Chief Commercial Officer” on June 05, 2018. More interesting news about Zai Lab Limited (NASDAQ:ZLAB) were released by: Streetinsider.com and their article: “Zai Lab Limited (ZLAB) Announces Exclusive Worldwide License Agreement with Crescendo Biologics for Innovative …” published on May 30, 2018 as well as Nasdaq.com‘s news article titled: “Zai Lab Announces Early Completion of Enrollment for ZL-2306 PK Study” with publication date: May 21, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: